Initial Phase 1 Dose Escalation Data of ORIC-114 in : vimars

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with...

Related Keywords

United States , California , South San Francisco , San Diego , Pratik Multani , Jacobm Chacko , Securities Exchange , Pharmaceuticals Inc , European Society Of Medical Oncology , Exchange Commission , Nasdaq , Linkedin , European Society , Medical Oncology , Escalation Data , Pharmacokinetic Analysis , Overcoming Resistance , Securities Act , Securities Exchange Act , Nasdaq Oric , Oric Pharmaceuticals ,